|
|
 |
|
聲明：本公司於專利期間不會製造、販賣、使用或出口下列之商業產品，或對下列產品為販賣之要約。
|
 |
| |
以下產品的取得依各個國家專利法的限制而不同
現有產品 (
有美國DMF或者EDMF者以藍色顯示)
|
Anastrozole |
Galantamine hydrobromide |
|
Argatroban |
Gemcitabine hydrochloride |
|
Azacitidine |
Granisetron hydrochloride |
|
Benazepril hydrochloride |
Irinotecan hydrochloride |
|
Bimatoprost |
Letrozole |
|
Bivalirudin |
Levonorgestrel |
|
Bortezomib |
Omeprazole |
|
Capecitabine |
Ondansetron hydrochloride |
|
Dantrolene sodium* |
Oxandrolone |
|
Decitabine |
Paclitaxel |
|
Desmopressin acetate |
Pemetrexed
2Na |
|
Docetaxel anhydrous |
Riluzole* |
|
Docetaxel trihydrate |
SN38 |
|
Entecavir* |
Tamsulosin hydrochloride |
|
Exemestane |
Topiramate |
|
Flavoxate hydrochloride |
Topotecan hydrochloride |
|
Flumazenil |
Travoprost |
|
Fluticasone propionate |
Zoledronic acid |
|
Fulvestrant |
|
*某些地區已屬獨家專售
開發中的產品
| |
Atazanavir sulfate |
Lapatinib ditosylate |
|
Clofarabine |
Lubiprostone |
|
Extenatide acetate |
Sunitinib malate |
| |
|
|
| |
|
|
| |
|
|
|
|
| |
|
